跳至主要内容
临床试验/CTRI/2024/09/073987
CTRI/2024/09/073987尚未招募不适用

A multicenter evaluation of the treatment persistence of advanced therapies (Biological disease-modifying agents and Targeted synthetic Disease Modifying Anti-Rheumatic Drugs) in the treatment of rheumatoid arthritis (RA): A Real World Evidence (RWE) study from India.

Pfizer Limited10 个研究点 分布在 1 个国家目标入组 225 人开始时间: 2024年9月23日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
225
试验地点
10
主要终点
Evaluate the treatment persistence/drug survival in patients on the advanced therapies

研究概览

简要总结

The aim of this study is to define treatment persistence, the parameters to change the therapy, the prescribing patterns of advanced therapies and to evaluate the effectiveness and safety of persistence of these therapies in the management of rheumatoid arthritis in a real world setting.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Patients aged 18 years and over diagnosed with RA eligible for treatment with advanced therapies (bDMARDs as well as tsDMARDs)
  • Agree to a minimum of 3 follow up visits with the rheumatologist.
  • Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

排除标准

  • Patients not willing to sign the informed consent document
  • Participation in a clinical trial during the past 6 months before enrolment into the study
  • Patients on therapy with bDMARDs/tsDMARDs for over 3 months.

结局指标

主要结局

Evaluate the treatment persistence/drug survival in patients on the advanced therapies

时间窗: 1 year

for rheumatoid arthritis.

时间窗: 1 year

次要结局

  • To study the effectiveness parameters as per the routine clinical practice and understand the real-world practice towards management of rheumatological disorders (DAS 28 scores, HAQ-DI scores or any other routine parameters evaluated).(Record the adverse events including serious adverse events, non-serious adverse events while on treatment during the study inclusion.)

研究者

申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Amod Tilak

Pfizer Limited

研究点 (10)

Loading locations...

相似试验